4 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2032. from the record
Of the 8 now held by other companies, 8 name Dri UK LP as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2032
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2034 · High confidence
Also notable
Ends Jul 2032 · High confidence
Also notable
Ends Mar 2040 · High confidence
Also notable
Ends Nov 2038 · High confidence
Inhibitors of Plasma Kallikrein
US 10,221,161
The most cited patent in this portfolio, cited by 26 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2034.
Benzylamine Derivatives as Inhibitors of Plasma Kallikrein
US 9,051,249
The most cited patent in this portfolio, cited by 26 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2032.
Enzyme Inhibitors
US 11,613,527
Granted 2023. Computed term ends 2040.
Solid Forms of a Plasma Kallikrein Inhibitor and Salts Thereof
US 11,584,735
Granted 2023. Computed term ends 2038.
Formerly held, still cited
Notable
Ends Nov 2035 · High confidence
N-((HET) Arylmethyl)-Heteroaryl-Carboxamides Compounds as Plasma Kallikrein Inhibitors
US 10,364,238
The most cited patent in this portfolio, cited by 27 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2035.
now held by Dri UK LP
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Benzylamine Derivatives as Inhibitors of Plasma Kallikrein (US 9,051,249) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
Recent changes
- Nov 10Assignment recorded on 1 record: Audhya, Utpaul Kumar and 4 others to Kalvista Pharmaceuticals Limited Recorded Nov 10, 2026, executed Mar 2, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76701, frame 421.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Enzyme Inhibitors | 1 in force | to Mar 2040 |
| Solid Forms of a Plasma Kallikrein Inhibitor and Salts Thereof | 1 in force | to Nov 2038 |
| Inhibitors of Plasma Kallikrein | 1 in force | to Aug 2034 |
| Benzylamine Derivatives as Inhibitors of Plasma Kallikrein | 1 in force | to Jul 2032 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,051,249 | Benzylamine Derivatives as Inhibitors of Plasma Kallikrein In force · High confidence | In force | High confidence | |
| US 10,221,161 | Inhibitors of Plasma Kallikrein In force · High confidence | In force | High confidence | |
| US 11,584,735 | Solid Forms of a Plasma Kallikrein Inhibitor and Salts Thereof In force · High confidence | In force | High confidence | |
| US 11,613,527 | Enzyme Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 8 patents in force now held by others · 13 patents ended · 9 applications pending · 18 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.